Ritlecitinib (Standard)

Overview

Ritlecitinib (Standard) is the analytical standard of Ritlecitinib ( HY-100754 ). This product is intended for research and analytical applications. Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1 , JAK2 , and TYK2 (IC50 >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15 . Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE).

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > CNS Infection | Products > Disease Areas > Experimental Autoimmune Encephalomyelitis | Products > Disease Areas > Experimental Autoimmune Encephalomyelitis | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Others | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > STAT | Products > Signaling Pathways > JAK | Products > Signaling Pathways > Reference Standards

Product Information

• Catalog No.: HY-100754R
• CAS No.: 1792180-81-4
• Molecular Formula: C15H19N5O
• Molecular Weight: 285.35
• Purity: 95%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source